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\s=b\Dementia and depression in patients
with Parkinson's disease have been re-
ported separately, but their prevalence is
controversial. This study examines the
coexistence of these two problems and
suggests a common underlying biochemi-
cal system. We examined these two enti-
ties by retrospective chart review and
cerebrospinal fluid biochemistry. We
found a prevalence of 10.9% for dementia,
51% for depression, and 5.4% for coinci-
dent depression and dementia. In a pro-
spective study of patients with Parkin-
son's disease we found a continuum of
cerebrospinal fluid 5-hydroxyindoleacetic
acid concentrations. Patients who were
either depressed or demented had lower
concentrations of this metabolite than
other patients with Parkinson's disease,
but patients who were depressed and de-
mented had the lowest levels. These re-
sults suggest that the coexistence of de-
mentia and depression represents a
unique clinical entity in Parkinson's dis-
ease. The serotonergic system may be in-
volved in depression and dementia be-
cause evidence of a cumulative effect on
this biochemical system is present.
(Arch Neurol. 1989;46:1284-1286)
"["Depression and dementia are the
most common behavioral distur¬
bances in idiopathic Parkinson's dis¬
ease (IPD) and each is associated with
distinctively different biochemical
mechanisms. Dementia has been asso¬
ciated with biologic and pathologic
changes in the cholinergic systems.
Choline acetyltransferase activity is
lower in demented patients with IPD
with and without pathologic changes
of Alzheimer's disease (AD)1 and anti-
cholinergic agents precipitate acute
confusional state in demented patients
with Parkinson's disease (PD).2 Corre¬
lations between the severity of demen¬
tia and the quantity of neurofibrillary
tangles and senile plaques have been
reported in PD,3 as have decreases in
the cholinergic neurons in the basal
forebrain.4 In addition, some authors
have suggested that the serotonergic
system is also affected in AD.5 D'Am¬
ato et al5 reported a decrease in the
number of serotonergic neurons in
both patients with AD and patients
with PD.
Depression in IPD has been related
to diminished serotonin, as assessed by
decreased concentration of cerebrospi¬
nal fluid (CSF) 5-hydroxyindoleacetic
acid (5-HIAA).6·7 The administration
of the serotonin precursor, 5-hydroxy-
tryptophan, may alleviate depression
in IPD.7 This study examined the pres¬
ence of coexisting depression and de¬
mentia in IPD, using retrospective




Subject Selection.—The medical records of
every patient with parkinsonism in an ur¬
ban hospital seen on all services during an
18-month period were reviewed. The popu¬
lation included private and clinic patients
with 90% receiving annual follow-up. How¬
ever, only data from the first contact during
the study period were included. This review
yielded 339 consecutively encountered pa¬
tients with IPD (78% inpatient; 22%
outpatient).8 The criteria for this diagnosis
included the presence of at least two of the
four motor manifestations of the disorder
(tremor, shuffling gait, bradykinesia, mus-
cular rigidity), with a history of insidious
onset. Patients with evidence of other
known causes of parkinsonism, including
postencephalitic, drug-induced, stroke-re¬
lated, and progressive supranuclear palsy
were excluded. Only patients with onset af¬
ter the age of 40 years were included to en¬
sure that patients had typical IPD.
Data Extraction.—A systematic data col¬
lection form to extract clinical information
from records was designed by us prior to the
survey. The first encounter was used to es¬
timate the prevalence of dementia and de¬
pression and any follow-up entries were
used to substantiate the initial impressions.
Consensus on criteria for the diagnoses of
depression and dementia was reached prior
to the study, and interrater agreement was
found to be high.8
Diagnoses.—Research diagnostic criteria
for primary degenerative dementia and the
criteria for major depression were based on
Diagnostic and Statistical Manual of Men¬
tal Disorders (DSM-III).9 Dementia is sus¬
tained impairment in intellectual function¬
ing that was not considered drug related
and without an alteration in consciousness.
A written description of mental status was
required and it had to include evidence of
impairment in memory, orientation, and
general knowledge. The details of this
method are based on the findings of Rajput
et al10 with modifications that have been
previously reported.8
The presence of depression was assessed
at the time of the study and excluded a his¬
tory of affective disorder. Depression is a
sustained dysphoric mood characterized by
feelings of sadness and associated with
changes in appetite and sleep habits. Fleet¬
ing or slight mood changes were excluded.
Results.—Using the criteria described, we
found that 37 patients (10.9%) were de¬
mented and 172 (51% ) were depressed. Sev¬
enteen patients (5.4%) had depression and
dementia (Table 1). The demented patients
and those with dementia and depression
were significantly older and had later onset
of PD symptoms than the other patients. In
addition this group had higher scores on the
PD Rating Scale, suggesting more severe
disease. The rate of dementia is signifi-
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Table 1.—Description of Groups in the Chart Review Study (N = 339)*
Not Depressed, Depressed and
Not Demented Demented Depressed Demented
_(n = 177)_(n = 17)_(n = 133)_(n = 12)
Age.t y_67.02 ± 9.0(a):t 76.29 ± 6.9( ) 66.84 ± 8.8(a) 74.53 ± 8.1(b)
Duration, y_9.05 ± 7.1_9.06 ± 7.2_7.89 ± 4.5_8.27 ± 4.4
Years of levodopa
treatment_5.58 ± 4.5_5.97 ± 4.8_6.35 ± 4.4_4.42 ± 3.6
Age of onset.t y 59.37 ± 9.8(a) 67.32 ± 10.3(b) 59.08 ± 9.6(a) 66.33 ± 9.7(b)
Symptom
severityt 26.18 ± 17.3(a) 50.39 ± 17.7(b) 37.91 ± 17.0(a) 50.25 ± 22.1(b)
* Values are means ± SDs.
tP< .001 for analyses of variance comparing all group means for each variable.
tMeans and SDs with the same letters (a.b) do not differ significantly In post hoc analyses.
Table 2.—Demographic Variables and Cerebrospinal Fluid Biogenic Amine Metabolites











Age, y 63.4 ± 9.3(bc) 72.4 ± 7.4(a) 62.7 ± 8.0(c) 1.6 ± 12.8t(ab)
Education, y 12.8 ± 3.7 14.0 ± 4.7 13.9 ± 3.9 14.0 ± 2.5
Duration, y 7.5 ± 5.5 7.9 ± 5.7 Ì.6 ± 4.2 10.9 ± 13.1
mMMS score 50.2 ± 6.5(a) 34.9 ± 10.2(b) 50.7 ± 4.6(a) 35.4 ± 8.7*(b)
HVA, ng/mL_45.2 ± 40.7 40.6 ± 27.4_49.1 ± 43.1_31.2 ± 18.8
MHPG, ng/mL 11.4 ± 6.9 8.0 ± 4.7 9.0 ± 5.1 3.0 ± 5.0
5-HIAA, ng/mL 20.9 ± 7.9(a) 15.8 ± 6.3(ab) 15.9 ± 6.1 (ab) 12.4 ± 4.8t:(b)
'Values are means ± SDs. Means and SDs with the same letters (a, b, c) do not differ significantly in post
hoc analysis. mMMS indicates modified Mini-Mental State Exam; HVA, homovanillic acid; MHPG, 3-methoxyl-
4-hydroxy-phenylglycol; and 5-HIAA, 5-hydroxyindoleacetlc acid.
tP < .001 for analyses of variance (ANOVAs) comparing all group means for each variable.
%P < .05 for ANOVAs comparing all group means for each variable.
cantly higher than would be predicted; it is
3.8 times greater than expected when com¬
pared with a population study that used
volunteers older than 60 years.11
Prospective Inpatient Studies
Subjects.—Over 5 years, 115 patients with
IPD encountered within the hospital or
outpatient services and giving informed
consent prior to hospital admission were
included. They participated in one of two
inpatient research protocols. In the initial
protocol, patients were taken off all treat¬
ment with dopamine agonist medications
before completing the psychiatric, neu¬
ropsychologic, and CSF measures.* In a
later protocol there was no medication
withdrawal and all procedures were com¬
pleted while patients were receiving opti¬
mal doses of levodopa (L-dopa) or a com¬
bination of - carbidopa and levodopa(Sinemet).6 Since the groups were compa¬
rable, they were combined for this report.
For comparison purposes, a group of pa¬
tients (N = 25) who met National Institute
of Neurological Communicative Disorders
and Stroke-Alzheimer's Disease and Re¬
lated Disorders Association criteria for
probable AD were included. These patients
were only mildly impaired and were not re¬
ceiving medication at the time of the study.
They were free of affective complaints and
participated in the neuropsychologic and
CSF studies described below.
Procedures.—Psychiatric Diagnosis.—
The Structured Clinical Interview was com-
pleted with each patient by a trained psy¬
chiatric interviewer. A diagnosis was de¬
rived according to DSM-III criteria.' When
needed, a family member was also inter¬
viewed to provide additional information.
The Hamilton Rating Scale of Depression
was also administered.
Neuropsychologic Studies.—Each pa¬
tient received a battery of neuropsychologic
tests measuring memory, attention, lan¬
guage, constructional ability, and general
cognition. These studies were used to con¬
firm the diagnosis of dementia according to
DSM-III criteria.
CSF Studies.—A lumbar puncture for
CSF was performed after 18 hours of
bed rest. Cerebrospinal fluid, 20 mL, was
removed and the metabolites of dopa¬
mine (homovanillic acid), serotonin (5-
HIAA), and norepinephrine 3-methoxyl-
4-hydroxy-phenylglycol (MHPG) were




Four groups of patients with IPD
were identified: demented (n = 31), de¬
pressed (n = 27), both demented and
depressed (n = 6), or unaffected(n = 46) (Table 2). As in the chart re¬
view study, the demented patients
were significantly older than the non¬
demented patients. However, those
who were depressed and demented
Table 3.—Comparison of
Demographic Data and Cerebrospinal
Fluid Biogenic Amine Metabolites in
Patients With Parkinson's Disease
and Alzheimer's Disease (n = 135)*
Alzheimer's Parkinson's
Disease Disease
(n = 25) (n = 110)
Age, y 68.1 ± 9.3 66.1 ± 9.5
mMMS score 39.6 ± 9.9 45.5 ± 10.2
MHPG, ng/mL 4.23 ± 2.9 3.82 ± 2.7
HVA, ng/mL 49.06 ± 47.5 44.0 ± 36.9
5-HIAA, ng/mL 28.5 ± 20.4 17.7 ± 7.4
'Values are means ± SDs. See Table 2 asterisk
footnote for explanation of abbreviations.
were not older than the other groups.
There were no other significant age
differences among groups. The de¬
mented and the demented and de¬
pressed groups had significantly lower
modified Mini-Mental State Examina¬
tion scores.
Patients with depression and de¬
mentia had significantly lower CSF 5-
HIAA levels than the unaffected group
with PD (Table 2). Patients who were(only) depressed or (only) demented
had CSF 5-HIAA levels that were
lower than the unaffected group with
PD and higher than the demented and
depressed group. However, these dif¬
ferences were not significant. There
was no significant difference among
the groups in homovanillic acid or
MHPG.
Although demented patients were
significantly older, age did not account
for the reduction in CSF 5-HIAA val¬
ues; the correlation between age and
CSF 5-HIAA was not significant (r =
-.037).
Table 3 summarizes comparisons be¬
tween patients with AD and IPD. The
groups did not differ in age. The group
with AD had significantly higher lev¬
els of CSF 5-HIAA than the patients
with IPD, a finding we have reported
previously.7 Performance on the mod¬
ified Mini-Mental State Examination,
a brief test of mental status, did not
differ in these two patient groups,
which is expected since the group with
IPD includes demented patients.
COMMENT
The present studies suggest that de¬
pression and dementia in IPD may
have a common biologic mechanism.
The demented and depressed patients
had significantly lower levels of the
serotonin metabolite, a finding that
has been reported in depressed pa¬
tients with PD by us6·7 and by others.13
It is unlikely that the association be¬
tween dementia and the serotonergic
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system is an artifact of the pseudode-
mentia of affective illnesses14 since
lowered 5-HIAA levels were also
present in demented patients who
were not depressed. Patients with de¬
pression and dementia had lower lev¬
els of the serotonergic metabolite than
those patients with either entity alone.
Although this difference was not sig¬
nificant, it may suggest an additive ef¬
fect of the two phenomena.
Much overlap exists between demen¬
tia in PD and AD. Neurofibrillary
plaques and tangles, the hallmark of
AD, have been identified in patients
with PD.1 There are also biochemical
similarities between PD and AD. Lev¬
els of CSF 5-HIAA can be reduced in
patients with AD,5 although we found
that the CSF 5-HIAA levels in patients
with AD were not as low as in patients
with PD.
In the chart review, prevalence of
dementia was significantly higher
than reported in an age-matched com¬
parison group. Dementia was associ¬
ated with patients with more severe
parkinsonism and older age of onset
than nondemented patients with PD.
Depression in PD was frequent in the
retrospective and the prospective
studies, although the actual preva¬
lence differed. Sampling and assess¬
ment techniques may account for
much of this variation, with a diagno¬
sis based on the presence of symptoms
of depression in the chart review yield¬
ing higher prevalence than diagnoses
made by direct interview. The de¬
pressed patients did not differ in age
and severity from the unaffected pa¬
tients with PD. However, the de¬
pressed group was younger than the
group with depression and dementia.
Perhaps depression is an early compli¬
cation of PD. One might speculate that
the occurrence of depression in PD
would increase the probability for de¬
mentia later.
The coexistence of depression and
dementia has been examined in other
populations. Kay et al15 found no asso¬
ciation between the diagnosis of de¬
pression and dementia in a sample of
community dwelling elderly. Others
have suggested that depression may be
an antecedent to dementia. In a clinic-
based population, referred for cogni¬
tive problems, more than half of the
patients initially diagnosed as being
depressed and not demented were
found to be demented at 3-year follow-
up assessment. Age was the only vari¬
able that was associated with the de¬
mented group, making it difficult to
determine the true impact of
depression.16 While the involvement of
a common biochemical system sug¬
gests an association between these en¬
tities, only a prospective study can de¬
termine if depression increases the
risk of dementia in PD.
In summary, the finding of lowered
serotonin metabolite levels in both de¬
pressed and demented patients sug¬
gests a common biochemical mecha¬
nism for both of these behavioral man¬
ifestations of PD. Coexisting dementia
and depression in PD may result from
a widespread degeneration of dopam¬
inergic, serotonergic, and presumably
cholinergic neurons.
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